Authors

Sagar Lonial, MD, Emory University School of Medicine

Latest:

Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma

Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.

Sagar Lonial, MD, FACP, Emory University School of Medicine

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University

Latest:

Influencing Factors to Initially Targeting BCMA in MM

Sagar Lonial, MD, Winship

Sagar Lonial, MD, Winship&nbsp

Sagar Lonial, MD, FACP, Winship Cancer Institute

Latest:

Investigational Agents for Relapsed/Refractory Myeloma

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

Sagar Lonial, MD, Winship Cancer Institute of Emory University

Sagus Sampath, MD

Latest:

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Sai-Hong I. Ou, MD

Latest:

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

Sai-Hong I. Ou, MD, PhD

Latest:

Dr. Ou on the FDA Approval of Pembrolizumab in SCLC

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

Sai-Hong Ignatius Ou, MD, PhD

Latest:

Dr. Ou on Alectinib as Treatment for NSCLC

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.

Sai-Hong Ignatius Ou, MD, PhD, University of California, Irvine School of Medicine

Sairah Ahmed, MD

Latest:

Dr. Ahmed on Optimizing Treatment With Axi-Cel in LBCL

Sairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.

Saketh Guntupalli, MD, University of Colorado School of Medicine

Salah-Eddin Al-Batran, MD

Latest:

Dr. Al-Batran on Future of Treatment in Gastric Cancer

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center

Latest:

Evidence-Based Treatment of Metastatic Gastric Cancer

Sam Donaldson

Latest:

Sam Donaldson on the Need for Optimistic Doctors

Former ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.

Sam J. Lubner, MD

Latest:

Finding Time: A Day in the Life of an Academic Oncologist

We all have to balance competing demands on our time. But as an academic oncologist, I have to keep a foot in 2 worlds, research and clinical, while still keeping my balance.

Sam S. Chang, MD, MBA

Latest:

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.